648
Views
18
CrossRef citations to date
0
Altmetric
Supplement 1, 2013

Evaluation of serum procathepsin B, cystatin B and cystatin C as possible biomarkers of ovarian cancer

, , , , &
Article: 21215 | Published online: 05 Aug 2013

Figures & data

Fig. 1. Procathepsin B concentration in serum and ascetic fluids of patients with ovarian cancer and benign tumours. a. Procathepsin B in serum of healthy persons of different age (ng/ml). b. Procathepsin B in serum and ascetic fluids of patients with ovarian cancer and benign tumours (ng/ml). The data are shown as mean±SEM. The number of patients is in parentheses.

Fig. 1. Procathepsin B concentration in serum and ascetic fluids of patients with ovarian cancer and benign tumours. a. Procathepsin B in serum of healthy persons of different age (ng/ml). b. Procathepsin B in serum and ascetic fluids of patients with ovarian cancer and benign tumours (ng/ml). The data are shown as mean±SEM. The number of patients is in parentheses.

Fig. 2. Cystatin B concentration in serum and ascetic fluids of patients with ovarian cancer and benign tumours (ng/ml). The data are shown as mean±SEM. The number of patients is in parentheses.

Fig. 2. Cystatin B concentration in serum and ascetic fluids of patients with ovarian cancer and benign tumours (ng/ml). The data are shown as mean±SEM. The number of patients is in parentheses.

Fig. 3. Cystatin C concentration in serum and ascetic fluids of patients with ovarian cancer and benign tumours (ng/ml). The data are shown as mean±SEM. The number of patients is in parentheses.

Fig. 3. Cystatin C concentration in serum and ascetic fluids of patients with ovarian cancer and benign tumours (ng/ml). The data are shown as mean±SEM. The number of patients is in parentheses.